Introduction
T lymphocytes are useful as therapeutic agents in viral diseases, 1,2 and cancer. [3] [4] [5] Genetic manipulation of T lymphocytes may improve their efficacy in adoptive immunotherapy, eg by the introduction of cytokine-encoding genes in tumor infiltrating T lymphocytes, 6 introduction of the adenosine deaminase (ADA) gene into T lymphocytes from SCID patients, 7, 8 expression of chimeric receptors on the membrane of T lymphocytes to endow tumor specificity, 9 or the transfer of suicide genes into donor T lymphocytes to control for allogeneic graft-versus-leukemia. 10 Up till now, retroviral gene transduction has been the most efficient and safe method for stable introduction of genes into cells. 11 The retroviral vector LXSN and derivatives 12 are widely used vectors for clinical application.
We have successfully engineered anti-CD3 activated human T lymphocytes with antigen receptor genes to redirect T lymphocytes to renal carcinoma cells (RCC).
These chimeric antigen receptor genes comprise the binding site of a RCC specific mAb, G250, and the signal transducing ␥-chain molecule of Fc(⑀)RI. We have shown that these chimeric receptor transduced activated human T lymphocytes can specifically recognize and lyse RCC target cells via the transduced chimeric Ig receptor (scFvG250) and produce cytokines following specific target cell interaction. However, the gene transduction efficiency obtained with the LXSN vector is low and requires repeated, laborious selection procedures. Moreover, although functional expression of the chimeric receptor is observed, the membrane expression levels are so low that it can not be detected by flow cytometry. A higher expression level of the chimeric receptor would (1) allow rapid screening and immunoselection of scFvG250 positive T lymphocytes; (2) facilitate receptor structurefunction analysis; (3) allow monitoring of trafficking and half-life of the gene transduced T lymphocytes following adoptive in vivo transfer to patients and overall quality control assessment; and (4) possibly prolong cytolytic capacity of the T lymphocyte.
In the last few years transient gene transduction systems have been reported that resulted in high titer production of retroviral vector particles, but these are either not readily available for clinical use, or not optimized for gene transduction of human T lymphocytes. [14] [15] [16] [17] Therefore we set out to construct a retroviral gene transduction system with high gene transduction efficiency and functional gene expression in activated human T lymphocytes. The 'STITCH' transient gene transduction system we developed consists of: (1) the retroviral vector pSTITCH encoding the transgene; (2) the plasmids pHIT60 16 and pCOLT-GALV encoding Moloney murine leukemia virus gag/pol and gibbon ape leukemia virus envelope, respectively; and (3) the human kidney cell line 293T as the packaging cell line. Cotransfection of all three constructs into 293T cells resulted in high titer production of GALV pseudotyped viral particles, which had earlier been shown to infect a wide range of cell types, including human T and B cells. 18, 19 In addition to efficient introduction of the scFvG250 chimeric gene into the activated human T lymphocytes, functional expression of chimeric single chain receptor requires passage through the quality control mechanism of the endoplasmic reticulum and proper protein folding, transportation to the membrane and linkage to the intracellular signalling pathways. In order to study the relation between gene structure and functional membrane expression, we designed seven different chimeric receptor gene constructs that vary in: (1) the configuration of the variable heavy and variable light chain sequences; (2) the hinge domain sequence; and (3) the sequence of the transmembrane domain and signal transducing cytoplasmic tail, and tested expression in 293T cells and activated human T lymphocytes using the 'STITCH' gene transduction system.
Here, we present the development of the 'STITCH' gene transduction system. We show that activated human T lymphocytes of multiple donors are efficiently transduced using the 'STITCH' system within 1 week. An increase in membrane expression of the scFvG250 chimeric receptor construct is observed using pSTITCH retroviral vector in comparison with LXSN vector. Different scFvG250 chimeric receptor gene constructs are functionally expressed in activated human T lymphocytes and their membrane expression levels are dependent on the structures of the scFv chimeric receptor gene dictating the protein three-dimensional structure.
Results

STITCH transient gene transduction system
The STITCH transient gene transduction system comprises: (1) pSTITCH retroviral vector; (2) plasmids pHIT60 and pCOLT-GALV; and (3) 293T packaging cells. Because clinical application of gene transduced activated human T lymphocytes requires high gene transduction efficiencies, it was developed to produce high titer of recombinant pseudotyped retroviral vectors in less then 1 week. pSTITCH retroviral vector contains splice donor/splice acceptor sides and the 5′ retroviral gag sequence for stable encapsidation, better transcription and packaging of the transgene as described for the MFG retroviral vector. 20 In addition, pSTITCH was constructed to contain both the human CMV IE promoter/enhancer and the SV40 ori to further increase the viral titer ( Figure 1 ). In combination with the use of the 293T packaging cell line, this was expected to result in high level of expression of the transgene because: (1) constructs containing the human CMV IE promoter/enhancer will be activated by adenovirus early proteins that are present in 293T cells; 21 and (2) 293T cells express the SV40 large T antigen which increases the copy number of constructs containing the SV40 ori. 16, 22 However, high level of retroviral particle production not only requires efficient expression of the transgene but also of the packaging plasmids. Therefore, the packaging plasmids pHIT60 and pCOLT-GALV also contain the human CMV IE promoter/enhancer and the SV40 ori (Figure 1 ). Indeed high titers of retroviral particles (10 7 infectious units/ml) were obtained by using the pSTITCH vector and 293T packaging cells. This was demonstrated after transfection of pSTITCH-lacZ vector and packaging plasmids in 293T cells and subsequent titration of the retroviral particles obtained on CF2TH cells and counting of the gene transduced cells after X-gal staining (data not shown).
Use of GALV envelope pseudotyped virus particles for gene transduction of activated human T lymphocytes results in higher gene transduction efficiency To determine the gene transduction efficiency of MoMLV and GALV env pseudotyped retroviral particles on the one hand and to investigate whether the efficiencies are donor-dependent on the other, we set out to transduce activated human T lymphocytes derived from six healthy donors with either GALV env pseudotyped or MoMLV retroviral particles. CD24 was used as a marker gene to determine the percentage of gene transduced T lymphocytes because CD24 can be expressed on the membrane of T lymphocytes and can easily be detected by flow cytometry. 23 Gene transduction of activated human T lymphocytes was accomplished after cocultivation of anti-CD3 activated PBL with irradiated 293T packaging cells producing pSTITCH-CD24 retroviral virus particles by using either GALV env or MoMLV env. The percentage of CD24 + T lymphocytes was determined by FACS with anti-CD24 Ig FITC conjugated. FACS analysis showed that the percentage of CD24 + T lymphocytes from all donors was higher after gene transduction using retroviral particles with GALV env (20%) than with MoMLV env (8%) ( Table 1) . It had to be excluded that the observed differences in gene transduction efficiency in T lymphocytes with GALV env pseudotyped and MoMLV retroviral vector particles were due to differences in viral titers. Hence, the infection of retroviral vector particles on CF2TH cells was determined because these cells are susceptible to gene transduction by GALV as well as MoMLV viruses. Infection of CF2TH cells showed an even better gene transduction efficiency with MoMLV env retroviral particles than with GALV pseudotyped retroviral particles (data not shown).
Increased membrane expression of scFvG250 chimeric receptor on activated human T lymphocytes following gene transfer with pSTITCH versus LXSN retroviral vector The STITCH gene transduction system has been developed to result in both high gene transduction efficiency and functional gene expression in activated human T lymphocytes. A high gene transduction efficiency of activated human T lymphocytes using pSTITCH retroviral vector with GALV env pseudotyped virus particles versus MLV env retroviral particles has been demonstrated. We also compared scFvG250 chimeric receptor gene expression in retroviral vector pSTITCH versus LXSN. Construct 'A', which contains the variable heavy chain linked to the variable kappa chain gene sequence of the mAb G250 and the ␥ chain of the Fc(⑀)RI (Figure 2a ), was used previously for gene transduction of activated human T lymphocytes. Activated human T lymphocytes were transduced with gene construct 'A' in LXSN retroviral vector and showed functional expression of the scFvG250 chimeric receptor, but the level of membrane expression could not be detected by flow cytometry even after G418 selection of the gene transduced T lymphocytes. 13 Transduction of activated human T lymphocytes derived from the same donor with construct 'A' in pSTITCH retroviral vector, however, resulted in a membrane expression of the chimeric receptor on the T lymphocytes as determined by flow cytometry after staining with anti-idiotype mAb (NUH-82) and goat-anti-mouse PE-conjugated ( Figure 4a ).
Construction of scFvG250 chimeric receptor genes
To optimize membrane expression which allows immunoselection of receptor expressing T lymphocytes, structure-function analysis and monitoring of gene-transduced T lymphocytes following adoptive in vivo transfer, seven different scFvG250 genes were constructed ( Figure 2 ). Replacement of the transmembrane region of the ␥ chain by the transmembrane CD4 region in construct 'B' removes the dimerization signal present in construct 'A'. This will result in expression of the scFvG250 as a monomeric molecule (Figure 2b ). It has been described that a spacer segment inserted between the scFv and the signal transducing chain is a structural prerequisite for antigen binding. 24 Constructs 'A' and 'B' contain only a small spacer region (15 aa), comprising a part of the constant kappa chain and an extracellular gene sequence, located between the scFvG250 and the transmembrane region. Thus, constructs 'C' and 'D' were generated to contain a longer spacer by inserting a long hinge region between the scFvG250 and the CD4 transmembrane region. A hinge sequence was selected consisting of the Ig heavy chain constant hinge-CH2-CH3 region to facilitate high level surface expression of chimeric receptors. 25 In addition, in construct 'C' the J K region was shortened from 11 to 3 aa to reduce the flexibility of the scFv and to acquire a more rigid, TCR-like structure. These scFvG250 constructs were coupled to the signal transducing TCR/CD3 chain (Figure 2c and d) . Finally, in order to study the effect that scFvG250 gene configuration may have on chimeric receptor protein folding, transport, membrane density and functional T lymphocyte membrane expression, constructs 'E', 'F' and 'G' were generated: the scFvG250 domain was inverted into variable kappa chain linked to the variable heavy chain (Figure 2e-g ).
Membrane expression levels of distinct scFvG250 molecules on 293T cells
To test the level of membrane expression of the scFvG250 constructs, gene transfection experiments with the pSTITCH scFvG250 constructs were performed in 293T cells. The 293T cells are very suitable to quantify expression of different retroviral vector constructs because transfection efficiencies of 50-70% can be obtained in these cells using the CaPO 4 transfection method. We assumed that protein folding and transport to the membrane of chimeric receptors in 293T cells would be representative for other human cells, including activated human T lymphocytes. CaPO 4 transfection of 293T cells with pSTITCH-scFvG250 constructs 'A' to 'G' resulted in membrane expression of scFvG250 receptor with five out of seven pSTITCH-scFvG250 constructs as analyzed by FACS after staining with NUH-31 mAb and goat-anti-mouse Ig PE-conjugated (Figure 3 ).
High level of membrane expression on activated human T lymphocytes by using pSTITCH-HKJCH2CH3CD4 construct To test if the observed difference in membrane expression of the scFvG250 (Figure 2 ) on 293T cells would also be found for activated human T lymphocytes, we compared the membrane expression of different scFvG250 chimeric ScFvG250 chimeric receptor membrane expression on activated human T lymphocytes results in RCC-specific cytolysis Different densities of scFvG250 chimeric receptor membrane expression were observed on scFvG250 gene transduced activated human T lymphocytes (Figure 4a -e). Therefore we tested the level of functional expression of scFvG250 constructs 'A' to 'E' on activated human T lymphocytes in cytotoxicity assays after gene transduction and immunoselection with NUH-31 mAb and magnetic beads ( Figure 5 ). Activated human T lymphocytes transduced with pSTITCH-HKCH2CH3CD4 construct (Figure 2c ) that did not show membrane expression of the chimeric receptor did not lyse G250 Ag pos RCC. Activated human T lymphocytes transduced with the four other constructs demonstrated high levels of G250 Ag pos RCC-
Figure 3 Cell surface expression of scFvG250 constructs on 293T cells. scFvG250 expression was determined by flow cytometry after transfection of 293T cells with different pSTITCH-scFvG250 constructs ('a'-'g' as indicated in Figure 2). Cells were stained by indirect immunofluorescence with 2 g/ml of the NUH-31 mAb followed by incubation with goat-antimouse Ig PE conjugated (GAM-PE). Data are presented in histograms with relative cell numbers on the y-axis and relative fluorescence intensity (FL2) on the x-axis in log scale.
specific lysis. Despite the different membrane expression densities, levels of RCC-specific cytolysis were similar.
Discussion
Genetic modification of activated human T lymphocytes allows receptor structure analysis in relation to its function and its signalling pathways. Moreover, it broadens application of human T lymphocytes in clinical adoptive Figure 2) immunotherapy. To this end, an efficient gene transduction system is required. Here we describe the development of a transient gene transduction system 'STITCH' that efficiently introduces genes into activated human T lymphocytes. This will ultimately allow the study of the influence of scFv gene structure; the distinct phases of gene transduction efficiency; DNA transcription; protein folding; intracellular transport; membrane expression; affinity of Ag recognition and signal transduction mechanisms. Transfection of pSTITCH retroviral vector, a GALV env gene construct and MoMLV gag-pol gene plasmids into 293T cells, resulted in production of retroviral vector particles with a titer of 10 7 c.f.u./ml in less than 1 week. High titer production of retroviral vector particles was the result of the combination of vector and packaging cell line in a transient virus producing system. Transient systems have been described earlier but are either not available for clinical applications or could be improved by increase of virus titer by incorporation of the SV40 ori in the retroviral vector. [14] [15] [16] [17] pSTITCH was constructed to contain the SFG vector regions that increases the titer of virus production, as well as expression level of the gene transduced in the cells as earlier described for MFG retroviral vector. 20, 26 Indeed, comparison of scFvG250 chimeric receptor gene expression in both LXSN and pSTITCH retroviral vector clearly showed a higher level of chimeric receptor expression using pSTITCH retroviral vector. Addition of CMV promoter and SV40 ori in pSTITCH was expected to result in a high level of protein production due to efficient CMV promoter regulated transcription and SV40 large T induced amplification of plasmid template in 293T cells. 16, 21 Together these features make pSTITCH vector very applicable for use in a transient packaging system using 293T cells. In addition to high titer production of retroviral particles, the efficiency of gene transduction is determined by the susceptibility of the type of target cell, eg activated human T lymphocytes, for gene transduction with the retrovirus. The receptor for GALV env viruses is expressed on hemopoietic stem cells at high levels and better gene transduction efficiencies were demonstrated in activated human T lymphocytes. 18, 19 We showed higher gene transduction efficiency with GALV env pseudotyped retroviral particles in activated human T lymphocytes derived from six individuals, demonstrating that this increased gene transduction efficiency is not donor-dependent.
Figure 4 Cell surface expression of scFvG250 construct on activated human T lymphocytes. scFvG250 expression was determined by flow cytometry after gene transduction of activated human T lymphocytes with different pSTITCH-scFvG250 constructs ('a'-'e' as indicated in Figure 2) after NUH-31 immunomagnetic selection. Gene transduced T lymphocytes were stained by indirect immunofluorescence with NUH-82 mAb (20 l culture supernatant) followed by incubation with GAM-PE. Data are presented in histograms with relative cell number on the y-axis and relative fluorescence intensity (FL2) on the x-axis in log scale and the mean fluorescence channel is indicated for each sample.
Figure 5 Cytotoxicity of pST-scFvG250-transduced activated human T lymphocytes against RCC. Activated human T lymphocytes transduced with different pSTITCH-scFvG250 constructs ('a'-'e' as indicated in
We reported earlier the construction and functional expression of a scFvG250 construct in activated human T lymphocytes using the retroviral vector LXSN. 13 Although we observed high levels of RCC-specific scFvG250-redirected cytolysis, the level of chimeric receptor surface expression on the gene transduced T lymphocytes was too low for detection by FACS analysis with anti-idiotype mAb. High level expression of the chimeric receptor would have several advantages because it will allow immunoselection of receptor expressing cells and structure-function analysis. Furthermore, it may improve cytolytic recycling capacity of the T lymphocyte. Functional membrane expression of chimeric receptors is a result of both gene transcription regulated by the retroviral vector and structure of the inserted chimeric receptor gene. The inserted gene must be translated into a protein, folded into the right configuration, passed through the endoplasmic reticulum control mechanism, transported to the membrane, expressed on the membrane and finally recognize Ag and transduce a functional signal into the T lymphocyte. We assume that man-made molecules like scFv chimeric receptors might not always fold in the right configuration and therefore may become degraded in the endoplasmic reticulum. 27 To study the effect of scFv gene structure on the membrane expression of the chimeric Ig receptor receptors, we generated seven different scFvG250 constructs and tested membrane expression on 293T cells ('A' to 'G') and activated human T lymphocytes ('A' to 'E') with pSTITCH retroviral vector. For five out of the seven scFvG250 gene constructs, gene transfers resulted in membrane expression on 293T cells, showing that these five gene products were properly folded. ScFvG250 membrane expression on 293T cells appeared representative for expression on the membrane of activated human T lymphocytes. To study membrane expression profiles of the different scFvG250 gene structures, transduced T lym-phocytes were enriched using immunoselection with anti-idiotype mAb-coated magnetic beads. FACS staining with anti-idiotype mAb of the enriched fractions showed different fluorescence profiles. Activated human T lymphocytes transduced with pSTITCH-HKJCH2CH3CD4 (construct 'D') showed the highest density of chimeric receptor membrane expression. Removal of eight aa of the G250 J K region in this scFvG250 construct completely abrogated scFvG250 membrane expression and function (construct 'C'). Hence, the presence of the complete J K gene region appears essential for functional membrane expression of scFvG250 chimeric receptors. Replacement of the 15 aa spacer region in construct 'A' by an Ig heavy chain constant hinge-CH2-CH3 region (construct 'D') resulted in an even more dense membrane expression on activated human T lymphocytes. We conclude that a small spacer sequence (15 aa) together with the complete Ig joining region is already sufficient for functional membrane expression of scFvG250 chimeric receptors. However, other, larger hinge regions, may result in distinct and higher levels of membrane expression. Moreover, the different profiles in membrane expression of the scFvG250 may also reflect differences in gene transfer efficiencies for the scFvG250 constructs.
ScFvG250 mediated antigen recognition and signal transduction triggered specific cytolysis by these T lymphocytes as was determined in short-term 51 Cr release assays. Four out of five scFvG250 chimeric receptors were functionally expressed on the activated human T lymphocytes and triggered T cell cytotoxicity. The levels of lytic activity were similar despite the differences in membrane density. These findings confirm our earlier observation that even at FACS-undetectable levels of scFvG250 chimeric receptor membrane expression on T lymphocytes of a panel of five different RCC lines were specifically lysed by these scFvG250 gene transduced T lymphocytes. 13 In conclusion, the 'STITCH' gene transduction system is efficient in: (1) expressing gene constructs in 293T cells for rapid screening of membrane expression; (2) production of high titer of retroviral vectors; and (3) introduction of genes and relatively high levels of gene expression in activated human T lymphocytes. We demonstrated efficient gene transduction of optimized scFvG250 chimeric gene constructs in these activated human T lymphocytes, resulting in high density of chimeric receptor membrane expression. Specific cytolysis of cancer cells expressing the relevant antigens was observed. These findings open the way to clinical application with chimeric receptors engineered human T lymphocytes. A clinical phase I/II study is in preparation.
Materials and methods
Cells and antibodies 293T cells (kindly provided by Dr Y Soneoka) and CF2TH cells (ATCC, CRL-1430) were cultured in DMEM medium (BioWhittaker, Verviers, Belgium) containing 10% BCS (Hyclone Laboratories, Logan, UT, USA), 100 U/ml penicillin and 100 g/ml streptomycin. PBL of healthy donors were isolated by centrifugation through Lymphoprep (d = 1077 g/cm 3 ) (Nycomed Pharma, Oslo, Norway) and activated in Mix-med culture medium (78% RPMI 1640 buffered with bicarbonate (2 g/l) and Hepes (25 mm) (BioWhittaker), 20% AIM-V (Life Technologies, Grand Island, NY, USA), 2% heat inactivated human serum, 2 mm glutamine, 100 U/ml penicillin and 100 g/ml streptomycin) 28 with 10 ng/ml OKT3 (Ortho Diagnostic System, Beerse, Belgium) at a density of 0.5 × 10 6 cells/ml. After 3 days of activation, lymphocytes were washed and cultured in RPMI culture medium (RPMI 1640 buffered with bicarbonate (2 g/l) and Hepes (25 mm), 10% heat inactivated human serum, 2 mm glutamine, 100 U/ml penicillin and 100 g/ml streptomycin) supplemented with 360 IU/ml human recombinant IL-2 (rIL-2) (Chiron, Amsterdam, The Netherlands). The following cell lines were used as targets in cytotoxicity assays: SK-RC-17 Cl.1 (mock-transfected RCC cell line) and SK-RC-17 Cl.4 (G250 Ag cDNA transfected RCC cell line) (kindly provided by E Oosterwijk, Nijmegen, The Netherlands). The antibodies used for staining the cells were: anti-idiotype mAb NUH-31 and NUH-82 (E Oosterwijk) and anti-CD24 (CLB-CD24; CLB, Amsterdam, The Netherlands).
STITCH gene transduction system
The basis of pSTITCH retroviral vector is SFG (kindly provided by Dr I Riviere) a derivative of MFG 20 which contains five mutations at the 5′ of the gag sequence. To construct the pSTITCH vector the U3 region of the 5′ LTR of SFG was replaced by the human CMV IE promoter/enhancer (isolated from PHIT110, kindly provided by Dr Y Soneoka, Oxford, UK) and the plasmid backbone contains the SV40 ori.
All constructs were introduced into pSTITCH by using a 5′ NcoI site and 3′ BamHI site. The HK␥ construct was made as described 13 and a NcoI site was introduced at the start codon by using PCR. The CD4 transmembrane region sequence (nucleotides 1258-1329) 29 and CD3 chain sequence (nucleotides 228-568) 30 were derived from mRNA of human PBL and human CTL clone D11, respectively, by reverse transcriptase followed by PCR. Short G250 joining gene region (J) contained only the first three of 11 aa of G250 J K and the first three of 14 aa of G250 J H . Hinge-CH2-CH3 region DNA (amino acid 11 of the hinge domain to 107 of the CH3) 31 was amplified by PCR from a plasmid containing genomic IgG1 DNA (kindly provided by Dr E Timmers). To generate the kappa-heavy (KH) configuration, the same strategy as for the HK␥ construct was followed. The coding sequence of CD24 was generated by PCR using PUC19-CD24 (kindly provided by Dr K Humphries, Vancouver, Canada) introducing a NcoI site at the transcription start codon and a BamHI site after the stop codon. LacZ sequence was isolated from pSV-␤-galactosidase (Promega, Madison, WI, USA) by PCR. For cloning into pSTITCH, a NcoI site was introduced at the start codon and a stop codon and a BamHI site was introduced at position 3754. For the transient packaging system the following plasmids are used: pHIT60, a LXSN-based vector containing the gag-pol genes of MLV retrovirus, pHIT456, a LXSN-based vector containing the MoMLV envelope gene, both containing the CMV IE promoter/enhancer and SV40 ori (both kindly provided by Dr Y Soneoka, Oxford, UK), 16 pCOLT-GALV a vector containing GALV env gene, CMV IE promoter/enhancer, ␤-globulin intron II and SV40 ori. Transfected cells were cultured for another 24 h after which the transfection medium was replaced by 10 ml of fresh medium. The following day, cells were analyzed by FACS for membrane expression of the inserted gene. For stable gene transduction, retroviral particles were generated after transfection of 293T cells with 20 g of pHIT60, pCOLT-GALV and pSTITCH retroviral vector by using CaPO 4 transfection. Twenty-four hours after transfection, cells were irradiated (25 Gy) and cocultured for 3 days with 0.5 × 10 6 anti-CD3 activated PBL/ml. Cocultivation was performed in RPMI culture medium (RPMI 1640 buffered with bicarbonate (2 g/l) and Hepes (25 mm), 10% heat inactivated human serum, 2 mm glutamine, 100 U/ml penicillin and 100 g/ml streptomycin) supplemented with 360 IU/ml human recombinant IL-2 (rIL-2) and 4 g/ml polybrene.
Determination of viral titer
For determination of the viral titer, retroviral particles were generated after transfection of 293T cells with 20 g of pHIT60, pCOLT-GALV and pSTITCH-lacZ retroviral vector by using CaPO 4 transfection. Twenty-four hours after transfection, medium was replaced by 5 ml of fresh medium. Retroviral supernatant was harvest after 24 h and filtered through a 0.45 m filter (Millipore, Molsheim, France) and diluted in medium. CF2TH cells (2 × 10 4 ) were seeded in six-well culture plates and 24 h later medium was replaced by viral supernatant dilutions supplemented with 8 g/ml polybrene (Sigma Chemical, St Louis, MO, USA). After 4 days, the percentage of positive colonies was counted after staining with X-gal. 32 Immunomagnetic purification of scFvG250 pos T lymphocytes scFvG250 pos T lymphocytes were purified by using immunomagnetic isolation with NUH-31 mAb. T lymphocytes (5 × 10 6 ) were incubated with 10 l NUH-31 mAb (2 g/ml) for 30 min at 4°C. After incubation cells were washed twice and resuspended in 250 l of culture medium. Magnetic particles (25 l) (Magnisort; Dupont, Wilmington, DE, USA) were washed twice and also resuspended in 250 l culture medium. Magnetic particles were added to the cells and incubated on a rollerbank for 30 min at 4°C. Following incubation, 9.5 ml medium was added and cells were selected against a magnet (Dynal, Oslo, Norway) for 10 min. Medium was replaced by fresh medium and magnet incubation was repeated. Medium from step 1 and 2 was pooled and another 10 min incubation against the magnet was performed. Cells containing the magnetic particles were cultured and 4 days later analyzed on FACS with antiidiotype mAb and goat-anti-mouse Ig PE conjugated for expression of the chimeric receptor.
Flow cytometry
The membrane expression of different molecules on 293T cells and T lymphocytes was measured by direct and indirect immunofluorescence and flow cytometry on a FACScan flow cytometer (Becton Dickinson, Mountain View, CA, USA). Cells were washed in PBS containing 1% BSA (PBS/BSA) and resuspended in 50 l of PBS/1% BSA. Fifty microliters of the diluted mAb was added and incubated for 30 min at 4°C. Cells were washed once in PBS/1% BSA and for the indirect fluorescence the second step antibody goat-anti-mouse Ig PE conjugated was added for 30 min at 4°C. After incubations cells were washed once in PBS/1% BSA, resuspended in 1% paraformaldehyde containing 1 g/ml 7-AAD (Brunswig Chemie, Edison, NJ, USA) and analyzed by flow cytometry. Treatment with goat-anti-mouse Ig PE conjugated served as control staining.
Cytotoxicity assay
Cytotoxic activity was measured in a 4-h 51 Cr release assay. Briefly, varying numbers of effector cells were added in triplicate to 96-well microtiter plates (100 l per well), followed by the addition of 2500 target cells (100 l) per well. The target cells were labeled with 50 Ci 51 Cr per 0.5 × 10 6 cells for 2 h at 37°C. At the end of the 4 h incubation period (37°C and 5% CO 2 ), supernatants were collected by using a Skatron harvesting system (Skatron, Lier, Norway) and counted in a gamma counter (Wallac, Breda, The Netherlands). Percentage specific lysis was calculated as follows: ((test counts − spontaneous counts)/(maximum counts − spontaneous counts)) × 100%.
